

25 PARALLEL SESSIONS INCLUDING 4 PROFFERED PAPERS SESSIONS

PARALLEL SESSION NUMBER 1

CHAIRMEN: Hans Petter Eikesdal (Norway) and Fausto Roila (Italy)

ROOM CAPACITY: Large

TIME: Friday 09:00-10:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Endocrine issues in cancer	Introduction	2 min	Fausto Roila	Italy
	Obesity, diabetes and cancer outcome	25 + 5 min	Pamela Goodwin	Canada
	Hypothyroidism after radiotherapy	15 + 5 min	Marianne F Rønjom	Denmark
	Endocrine disorders following treatment with tyrosine kinase inhibitors	20 + 5 min	Fausto Roila	Italy
Abstract 25-4-O	INCIDENCE OF DIABETES INDUCED BY HIGH-DOSE GLUCOCORTICOID TREATMENT IN CANCER PATIENTS	7 + 3 min	Helga Schultz	Denmark
	Conclusion	3 min	Hans Petter Eikesdal	Norway

PARALLEL SESSION NUMBER 2

CHAIRMEN: Dorothy Keefe (Australia) and Birgitte Grube (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 09:00-10:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Use of E-Health in Supportive Care	Introduction	3 min	Dorothy Keefe	Australia
	E-Health is empowered health Nurses experience	20 + 5 min	Bodil Westman	Sweden
	How can e-health increase adherence to cancer therapy and supportive care? Physicians experience	20 + 5 min	Dorothy Keefe	Australia
	E-health Patients experience	20 + 5 min	Jane Pelouchova	Czech Republic
Abstract 04-1-O	WEB-SUPPORTED INFORMATION NEEDS OF CAREGIVERS IN HEMATOLOGIC CANCER	7 + 3 min	G Yigit	Turkey
	Conclusion	2 min	Birgitte Grube	Denmark

PARALLEL SESSION NUMBER 3

CHAIRMEN: Patrick Combrez (Belgium) and Lars Kjeldsen (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 09:00-10:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Best Supportive Care in Patients with Haematological Malignancies	Introduction	2 min	Patrick Crombez	Belgium
	Supportive Care in Haematology	15 min	Lars Kjeldsen	Denmark
	General Management of Neutropenic Patients	15 min	Patrick Crombez	Belgium
	Nursing Evidence and Controverses in Infection Prevention	15 min	Arno Mank	The Netherlands
	Outpatient Bone Marrow Transplantation	15 min	William Hogan	USA
Abstract 08-2-O	RISK OF HYPONATRAEMIA IN CANCER PATIENTS TREATED WITH TARGETED THERAPIES: A META-ANALYSIS OF CLINICAL TRIALS.	7 + 3 min	Rossana Berardi	Italy
	Panel discussion	15 min	All	
	Conclusion	3 min	Lars Kjeldsen	Denmark

PARALLEL SESSION NUMBER 4

CHAIRMEN: Christoffer Steer (Australia) and Trine Lembrecht Jørgensen (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 09:00-10:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Supportive Care in the Elderly	Introduction	2 min	Trine Lembrecht Jørgensen Denmark
	Is Cancer Symptom Control Any Different in Older Adult Cancer Patients?	20 + 2 min	Aminah Jatoi USA
	Pain control in the elderly	20 + 2 min	Eduardo Bruera USA
	Nursing Facilities and Cancer Supportive Care: Providing Best Practices Clinical Services To Older Adult Cancer Patients	20 + 2 min	Bente Appel Esbensen Denmark
Abstract 07-1-O	INPUT OF A PHARMACIST-LED MEDICATION EVALUATION IN THE MANAGEMENT OF OLDER PATIENTS WITH CANCER	7 + 3 min	Myriam Aitichou France
Abstract 07-2-O	CHARLSON COMORBIDITY INDEX AS A PREDICTOR OF OVERALL SURVIVAL FOR PATIENTS WITH EARLY STAGE NSCLC?	7 + 3 min	Stefan S Jeppesen Denmark
	Chairman's conclusion	2 min	Christoffer Steer Australia

PROFFERED PAPERS - PARALLEL SESSION NUMBER 5

CHAIRMEN: Sebastiano Mercadante (Italy) and Svend Ottesen (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 09:00-10:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Psychooncology and Quality of Life	Introduction	1 min	Svend Ottesen	Denmark
18-1-O	CANCER CAREGIVER QUALITY OF LIFE: NEED FOR TARGETED INTERVENTION	8 + 3 min	Maria Lapid	USA
18-2-O	EXPECTATION EFFECTS IN ENDOCRINE TREATMENT OF BREAST CANCER: A TWO-YEAR PROSPECTIVE CLINICAL COHORT STUDY	8 + 3 min	Yvonne Nestoriuc Young Investigator Winner	Germany
18-3-O	ESTROGEN RECEPTOR ALPHA (ESR1) GENETIC POLYMORPHISMS AND THE RISK OF CHEMOTHERAPY-ASSOCIATED COGNITIVE IMPAIRMENT IN EARLY-STAGE BREAST CANCER (ESBC) PATIENTS	8 + 3 min	Terence Ng Outstanding Young Investigator	Singapore
18-4-O	RELATIONSHIP BETWEEN SUBJECTIVE AND ACTIGRAPHY-MEASURED SLEEP IN 237 PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)	8 + 3 min	Oxana Palesh	USA
18-5-O	THE CONTRIBUTION OF INFORMAL CAREGIVERS IN CANCER CARE, AND PATIENT FACTORS ASSOCIATED WITH CAREGIVER OUTCOMES	8 + 3 min	Anna Ugalde	Australia
22-1-O	QUALITY OF LIFE IN ELDERLY/FRAIL PATIENTS WITH GLIOBLASTOMA MULTIFORME: RESULTS OF THE IAEA RANDOMIZED PHASE III STUDY COMPARING SHORT AND STANDARD COURSE OF RADIOTHERAPY	8 + 3 min	Elena Fidarova	Austria
22-2-O	VALIDATION OF THE EORTC QLQ-INFO 25 QUESTIONNAIRE IN LEBANESE CANCER PATIENTS: REVEALING A STATE OF BLISSFUL IGNORANCE?	8 + 3 min	Samer Tabchi	Lebanon
22-3-O	CONFLICT, PARENT DISTRESS, FAMILY STRAIN AND HEALTH-RELATED SYMPTOMS IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	8 + 3 min	I-Chan Huang	USA
	Conclusion	1 min	Sebastiano Mercadante	Italy

PARALLEL SESSION NUMBER 6

CHAIRMEN: Marianne Ewertz (Denmark) and Michael Ewer (USA)

ROOM CAPACITY: Large

TIME: Friday 14:30-16:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Cancer Therapy-Induced Cardio-Pulmonary Toxicity	Introduction	1 min	Marianne Ewertz	Denmark
	Cardiotoxicity induced by chemotherapy and targeted therapy	35 + 4 min	Michael Ewer	USA
	Pulmonary toxicity induced by chemotherapy and targeted agents	25 + 4 min	Richard Gralla	USA
Abstract 26-5-O	PRIMARY VERSUS SECONDARY CARDIOTOXICITY OF ANTI-CANCER TREATMENT: A DISTINCTION WITH BROAD IMPLICATIONS	7 + 3 min	Michael Ewer	USA
Abstract 24-6-O	RISK OF CARDIOVASCULAR DISEASE AMONG CANCER SURVIVORS AND AGE- AND GENDER-MATCHED CONTROLS	7 + 3 min	Dounya Schoormans	The Netherlands
	Conclusion	1 min	Marianne Ewert	Denmark

PARALLEL SESSION NUMBER 7

CHAIRMEN: Siri Beier Jensen (Denmark) and Deborah P. Saunders (Canada)

ROOM CAPACITY: Medium

TIME: Friday 14:30-16:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Oral Care in Head and Neck Cancer	Introduction	2 min	Siri Beier Jensen	Denmark
	Translating MASCC/ISOO research into patient-centered care: Multidisciplinary phased oral care for patients undergoing head and neck radiation	25 + 3 min	Deborah P. Saunders	Canada
	Focus on taste disturbances	15 + 2 min	Anna Boltong	Australia
	Focus on nutrition	15 + 2 min	Harriet Jager-Wittenaar	The Netherlands
Abstract 15-1-O	STIMULATED RESIDUAL SALIVARY GLAND FUNCTION IS CORRELATED TO MEAN RADIATION DOSE DELIVERED TO THE MAJOR SALIVARY GLANDS DURING RADIOTHERAPY FOR HEAD AND NECK CANCER	10 + 2 min	Ruta Zukauskaitė	Denmark
Abstract 15-2-O	ORAL AND DENTAL STATUS IN LONG- TERM SURVIVORS OF ALLOGENEIC HSCT PERFORMED IN CHILDHOOD, ADOLESCENTS OR YOUNG ADULTHOOD -PRELIMINARY RESULTS	10 + 2 min	Kristine Eidal Tanem	Norway
	Concluding remarks	2 min	Deborah P. Saunders	Canada

PARALLEL SESSION NUMBER 8

Joint session FSK, EONS and MASCC

CHAIRMEN: Andreas Charalambous (Cyprus) and Alex Molassiotis (Hong Kong)

ROOM CAPACITY: Large

TIME: Friday 14:30-16:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Complementary and Alternative Medicine in Cancer Care	Introduction	3 min	Alex Molassiotis Hong Kong
	CAM in Cancer Care: New data call for mind shifting?	20 min	Andreas Charalambous Cyprus
	What is the evidence of CAM in cancer patients	20 min	Helle Johannessen Denmark
	Clinical Use of CAM in Cancer Patients	20 min	Alex Molassiotis Hong Kong
Abstract 04-2-O	COMPLEMENTARY MEDICINE EDUCATION FOR ONCOLOGY PROFESSIONALS IN ALBERTA: EVALUATION OF AN ONLINE PROGRAM	7 + 3 min	Gregory Levin Canada <i>Young Investigator Winner</i>
	Discussion	15 min	
	Conclusion	2 min	Andreas Charalambous Cyprus

PARALLEL SESSION NUMBER 9

CHAIRMEN: Jean Jacques Body (Belgium) and Carina Ørts Christensen (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 14:30-16:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Bone Health	Introduction	1 min	Carina Ørts Christensen Denmark
	Prevention of osteoporosis in cancer patients	15 min	Jean Jacques Body Belgium
	Bone metastases: what is new and what is targeted?	15 min	Matti S. Aapro Switzerland
	Recognition and management of osteonecrosis of the jaw	15 min	Cesar Migliorati USA
Abstract 01-1-O	TREATMENT AND PREVENTION OF OSTEONECROSIS OF THE JAW ASSOCIATED WITH MEDICATION:2009-2014	7 + 3 min	E. Papadopoulou Greece
Abstract 01-2-O	PALLIATIVE SURGICAL INTENT IN THE TREATMENT OF BONE SARCOMAS: A MIDTERM REVIEW FROM A RESOURCE CHALLENGED ENVIRONMENT	7 + 3 min	SA Khan India
Abstract 01-3-O	RISK OF OSTEOPOROSIS SUBSEQUENT TO CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER	7 + 3 min	Carina Ørts Christensen Denmark
	Optimising Bone Health: Discussion	12 min	All
	Conclusion	2 min	Jean Jacques Body Belgium

PROFFERED PAPERS - PARALLEL SESSION 10

CHAIRMEN: Andrea Cheville (USA) and Julie Silver (USA)

ROOM CAPACITY: Medium

Time: Friday 14.30-16:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Rehabilitation and survivorship	Introduction	1 min	Andrea Cheville	USA
24-1-O	COMPARING THE COSTS OF THREE PROSTATE CANCER FOLLOW-UP STRATEGIES: A COST-MINIMISATION ANALYSIS	8 + 3 min	Alison Pearce Young Investigator Winner	Jamaica
24-5-O	IMPLEMENTATION OF THE PROSTATE CANCER SUPPORTIVE CARE (PCSC) PROGRAM, A COMPREHENSIVE APPROACH FOR MEN WITH PROSTATE CANCER (PC) AND THEIR PARTNERS	8 + 3 min	S L Goldenberg	Canada
24-2-O	QUALITY OF LIFE, HEALTH AND PERSONAL WELLBEING UP TO TWO YEARS FOLLOWING CURATIVE INTENT COLORECTAL CANCER SURGERY: RESULTS FROM THE UK COLORECTAL WELLBEING (CREW) STUDY	8 + 3 min	Claire Foster	United Kingdom
24-3-O	PREOPERATIVE ANAEMIA AND BLOOD-TRANSFUSION AS PROGNOSTIC FACTORS FOR MORTALITY IN COLORECTAL CANCER - A SWEDISH COHORT STUDY	8 + 3 min	Malin Mörner	Sweden
23-7-O	IMPROVING ADHERENCE TO CANCER TREATMENT BY ADDRESSING QUALITY OF LIFE IN PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS	8 + 3 min	J Basford	Canada
23-3-O	IMPACT AND FEASIBILITY OF AN EXERCISE PROGRAM DURING CHEMO-RADIOTHERAPY IN HEAD AND NECK CANCER SURVIVORS:A RANDOMIZED CONTROLLED TRIAL	8 + 3 min	Stephen Samuel Young Investigator Winner	India
23-4-O	INSULIN-LIKE GROWTH FACTORS ARE MODULATED BY EXERCISE IN BREAST CANCER SURVIVORS: A META-ANALYSIS WITH META-REGRESSION	8 + 3 min	Jose F M Echávez	Colombia
23-6-O	SEXUALITY AND SEXUAL FUNCTION ONE YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	8 + 3 min	Kristina Nørskov	Denmark
	Conclusion	1 min	Julie Silver	USA

PARALLEL SESSION NUMBER 11

CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South Africa)

ROOM CAPACITY: Large

TIME: Friday 17:45-19:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Bone marrow toxicity	Introduction	2 min	Mario Dicato	Luxembourg
	Anemia in cancer: an update of the use of iron, EPO and activin receptor antagonists	17 + 3 min	Matti Aapro	Switzerland
	Febrile neutropenia: an update of outpatient management of low risk patients	12 + 3 min	Jean Klastersky	Belgium
	Febrile neutropenia: an update of management of high risk - stem cell transplantation patients	12 + 3 min	William Hogan	USA
	Thrombocytopenia and thrombopoietin	12 + 3 min	Mario Dicato	Luxembourg
Abstract 26-2-O	INTRAVENOUS IRON ISOMALTOSIDE 1000 (MONOFER®) AS MONO THERAPY IN COMPARISON WITH ORAL IRON SULPHATE IN PATIENTS WITH NON-MYELOID MALIGNANCIES ASSOCIATED WITH CHEMOTHERAPY INDUCED ANAEMIA (CIA)	7 + 3 min	G Birgegård	Sweden
Abstract 13-1-O	BIOSIMILAR FILGRASTIM AND CHEMOTHERAPY-INDUCED NEUTROPENIA: OVERALL RESULTS OF THE NEXT STUDY	7 + 3 min	D Kamioner	France
	Conclusion	3 min	Bernardo Rapoport	South Africa

PARALLEL SESSION NUMBER 12

CHAIRMEN: Mario Lacouture (USA) and Inge Marie Svane (Denmark)

ROOM CAPACITY: medium

TIME: Friday 17:45-19:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Novel Therapies and Best Supportive Care in Cutaneous Malignancies	Introduction	5 min	Mario Lacouture	USA
	Efficacy of agents targeting the BRAF/MEK pathway	15 min	Peter Arne Gerber	Germany
	Discussion	5 min		
	Efficacy of immune checkpoint inhibitors	15 min	Inge Marie Svane	Denmark
	Discussion	5 min		
	Systemic toxicities from BRAF/MEK pathway and Immune check point inhibitors	15 min	Vincent Sibaud	France
	Discussion	5 min		
	Dermatologic toxicities from BRAF/MEK pathway and Immune check point inhibitors	15 min	Mario Lacouture	USA
	Discussion	5 min		
	Conclusion	5 min	Inge Marie Svane	Denmark

PARALLEL SESSION NUMBER 13

CHAIRMEN: Petra Feyer (Germany) and Marianne Ewertz (Denmark)

ROOM CAPACITY: Medium

TIME: Friday 17:45-19:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Radiotherapy-induced Late Toxicities in Cancer Survivors	Introduction	2 min	Marianne Ewertz	Denmark
	Late Complications Induced by Radiotherapy in Head and Neck Cancer Patients	20 + 5 min	Petra Feyer	Germany
	Carditoxicity induced by radiotherapy	20 + 5 min	Sarah C Darby	United Kingdom
	Gastrointestinal late complications of radiotherapy	20 + 5 min	Ann Muls	United Kingdom
Abstract 25-3-O	COMPARISON OF BENEFITS, SAFETY OF 8% VERSUS 4% FORMALIN FOR TREATMENT OF CHRONIC HEMORRHAGIC RADIATION PROCTITIS IN PATIENTS OF CERVICAL CARCINOMA: A RANDOMIZED CONTROLLED TRIAL	7 + 3 min	Mukesh Singhal	India
	Conclusion	3 min	Petra Feyer	Germany

PROFFERED PAPERS - PARALLEL SESSION 14

CHAIRMEN: Paul Hesketh (USA) and Rajesh Lalla (USA)

ROOM CAPACITY: Medium

TIME: Friday 17:45-19:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Gastro-intestinal toxicity	Introduction	1 min	Paul Hesketh USA
11-2-O	ANTIEMESIS PROPHYLAXIS AMONG BREAST CANCER (BC) PATIENTS RECEIVING ANTHRACYCLINE-BASED CHEMOTHERAPY: A POPULATION-BASED STUDY.	8 + 3 min	Mariana Chavez USA Mac Gregor Young Investigator Winner
11-3-O	EFFICACY AND SAFETY OF ROLAPITANT FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF HIGHLY- OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC; MEC)	8 + 3 min	Bernardo Rapoport South Africa
11-4-O	ROLE OF OLANZAPINE IN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ON PLATINUM BASED CHEMOTHERAPY PATIENTS; A RANDOMIZED CONTROLLED STUDY	8 + 3 min	Sandip Mukhopadhyay India
11-5-O	THE ORAL ADMINISTRATION OF THE BRAIN PENETRATING GHRELIN AGONIST, HM01, ANTAGONIZES CISPLATIN-INDUCED EMESIS IN SUNCUS MURINUS (HOUSE MUSK SHREW)	8 + 3 min	John Rudd Hong Kong
11-6-O	SINGLE- VERSUS MULTIPLE-DAY CORTICOSTEROID DOSING FOR DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING	8 + 3 min	Pamela Ng Canada
10-3-O	TIGHT JUNCTION DISRUPTION IS SEEN IN THE ORAL CAVITY OF PATIENTS RECEIVING STANDARD DOSE CHEMOTHERAPY.	8 + 3 min	Hannah Wardill Australia
10-4-O	DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED ASSESSMENT TOOL FOR SYSTEMIC THERAPY-INDUCED DIARRHEA	8 + 3 min	Michelle Lui Canada
10-5-O	ASSOCIATION BETWEEN ORAL MICROBIOME AND MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANT SUBJECTS	8 + 3 min	Farah Mougeot USA
	Conclusion	1 min	Rajesh Lalla USA

PARALLEL SESSION NUMBER 15

CHAIRMEN: Matti Aapro (Switzerland) and Didier Kamioner (France)

ROOM CAPACITY: Medium

TIME: Saturday 10:30-12:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
MASCC AFSOS Symposium	Introduction	2 min	Matti Aapro	Switzerland
	Pharmacist in Cancer Care Unit; A Role for Quality of Care?	10 min	Jean Baptiste Rey	France
	Discussion	5 min		
	Back Home: Evidence for Supportive Network; how, when and for who ?	10 min	Manon Lemonde	Canada
	Discussion	5 min		
	Mucositis Guidelines : An Update	10 min	RJ Bensadoun	France
	Discussion	5 min		
	Breathlessness at the Palliative Time : From Guidelines to Practice	10 min	Claudia Mazzocato	Switzerland
	Discussion	5 min		
	European Supportive Care Associations in MASCC: from AFSOS to NICSO (Roundtable discussion)	25 min	Petra Feyer Carla Ripamonti Ivan Krakowski	Germany Italy France
	Conclusion	3 min	Didier Kamioner	France

PARALLEL SESSION NUMBER 16

CHAIRMEN: Karin Olson (Canada) and Eric van Muilekom

ROOM CAPACITY: Medium

TIME: Saturday 10:30-12:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Fatigue	Introduction	2 min	Eric van Muilekom	The Netherlands
	How do we define fatigue and what is new?	15 + 0 min	Karin Olson	Canada
	Cancer-related sleep disturbances	15 + 5 min	Poul Jennum	Denmark
	Compassion fatigue: How to deal with it?	15 + 5 min	Eric van Muilekom	The Netherlands
	Fatigue in advanced cancer	15 + 5 min	Andreas Charalambous	Cyprus
Abstract 06-1-O	RANDOMIZED TRIAL OF YOGA VERSUS STRENGTHENING EXERCISES IN BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE	7 + 3 min	Daniela Stan	USA
	Conclusion	3 min	Karin Olson	Canada

PARALLEL SESSION NUMBER 17

CHAIRMEN: Charles Loprinzi (USA) and Lise Eckhoff (Denmark)

ROOM CAPACITY: Medium

TIME: Saturday 10:30-12:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Neurological Complications	Introduction	1 min	Charles Loprinzi	USA
	Genomic risks for developing CIPN	20 + 3 min	Lise Eckhoff	Denmark
	Treatment of CIPN	20 + 3 min	Charles Loprinzi	USA
	Evidence-based caring for patients with CIPN	20 + 2 min	Anita Margulies	Switzerland
Abstract 12-1-O	CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS: INFLUENCE ON QUALITY OF LIFE AND VALIDATION OF A QUESTIONNAIRE FOR DAILY CLINICAL PRACTICE	7 + 3 min	Antoinetta Beijers	The Netherlands
Abstract 12-2-O	CAN PREGABALIN PREVENT PACLITAXEL-ASSOCIATED NEUROPATHY?—A PILOT TRIAL	7 + 3 min	Shivani Shinde	USA
	Conclusion	1 min	Lise Eckhoff	Denmark

PARALLEL SESSION NUMBER **18 joint session IASLC/MASCC**

CHAIRMEN: Richard Gralla (USA) and Wilfried Ernst E Eberhardt (Germany)

ROOM CAPACITY: Large

TIME: Saturday 10.30-12:00

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Supportive Care in Lung Cancer	Introduction	3 min	Richard Gralla	USA
	Management of NSCLC – state of the art	20 min	Wilfried Ernst E Eberhardt	Germany
	Dyspnea – magnitude of the problem and management	15 min	Sam Ahmedzai	United Kingdom
	New options in the management of hyponatremia	10 min	Mellar Davis	USA
	Quality of life in lung cancer	15 min	Richard Gralla	USA
Abstract 24-4-O	OVERALL SURVIVAL AFTER PALLIATIVE THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER NOT SUITABLE FOR CURATIVE INTENDED TREATMENT	7 + 3 min	Olfred Hansen	Denmark
	How to optimize supportive care in lung cancer?	15 min	Round table discussion	All
	Conclusion	2 min	Wilfried Ernst E Eberhardt	Germany

PARALLEL SESSION NUMBER 19

CHAIRMEN: Sebastiano Mercadante (Italy) and Sam Ahmedzai (United Kingdom)

ROOM CAPACITY: Large

TIME: Saturday 13:00-14:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Cancer Pain – Opioids and Beyond	Introduction	2 min	Sebastiano Mercadante Italy
	Neuronal mechanisms and targeted therapy of bone cancer pain	20 + 5 min	Sam Ahmedzai United Kingdom
	Understanding visceral pain - origins and treatments	15 + 5 min	Sebastiano Mercadante Italy
	Cancer pain at the end of life – rational and realistic management choices	15 + 5 min	Eduardo Bruera USA
Abstract 03-1-O	EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMAB AS ADJUNCTIVE THERAPY FOR CANCER-RELATED PAIN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY	7 + 3 min	Neal Slatkin USA
Abstract 03-2-O	COMPARISON OF UPPER AND LOWER EXTREMITY CHARACTERIZATIONS OF CHEMOTHERAPY-INDUCED NEUROPATHY (CIN) USING PATIENT REPORTED OUTCOME MEASURES	7 + 3 min	Christine Miakowski USA
	Conclusion	3 min	Sam Ahmedzai United Kingdom

PARALLEL SESSION NUMBER 20

CHAIRMEN: Mario Lacouture (USA) and Jennifer Choi (USA)

ROOM CAPACITY: medium

TIME: Saturday 13:00-14:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Skin toxicity	Introduction	5 min	Jennifer Choi	USA
	Assessment of skin toxicity	20 min	Christine Boers-Doets	NED
	Case 1 (chemotherapy)	5 min	Mario Lacouture	USA
	Discussion	10 min	Moderator: Jennifer Choi	USA
	State of the art: chemotherapy-induced skin toxicity	15 min	Mario Lacouture	USA
	Case 2 (targeted therapy)	5 min	Jennifer Choi	USA
	Discussion	10 min	Moderator: Mario Lacouture	USA
	State of the art: targeted therapy-induced skin toxicity	15 min	Jennifer Choi	USA
	Conclusion	5 min	Mario Lacouture	USA

PARALLEL SESSION NUMBER 21

CHAIRMEN: Charles Loprinzi (USA) and Tom Møller (Denmark)

ROOM CAPACITY: Large

TIME: Saturday 13:00-14:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Supportive Care in Breast Cancer – the Significance of Life Style	Introduction	1 min	Charles Loprinzi Loprinzi USA
	Use of Exercise in Patients with Breast Cancer	15 min	Tom Møller Denmark
	Q & A	5 min	
	Healthy Diet and Lifestyle for Breast Cancer Patients	15 min	Christina Lacerda Portugal
	Q & A	4 min	
	Smoking as an Independent Risk Factor for Radiotherapy- Induced Skin Reactions in Breast Cancer	15 min	Lena Sharp Sweden
	Q & A	4 min	
Abstract 26-3-O	RACIAL DIFFERENCES IN EARLY SYMPTOM MANAGEMENT, HOSPICE USE, AND INTENSITY OF END-OF-LIFE CARE AMONG ELDERLY WOMEN WITH BREAST CANCER	7 + 3 min	Devon Check USA
Abstract 23-5-O	THE EFFECT OF EXERCISE TRAINING ON MEDIATORS OF TUMOUR PROGRESSION IN BREAST CANCER SURVIVORS: A META-ANALYSIS	7 + 3 min	Jose F M Echávez Colombia
Abstract 09-1-O	STANDARDIZING LYMPHEDEMA ASSESSMENT PRACTICES: A QUALITY IMPROVEMENT INITIATIVE IN ALBERTA CANADA	7 + 3 min	Margaret McNeely Canada
	Conclusion	1 min	Tom Møller Denmark

PARALLEL SESSION NUMBER 22

CHAIRMEN: Richard Gralla (USA) and Jørn Herrstedt (Denmark)

ROOM CAPACITY: Large

TIME: Saturday 14:45-16:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Chemotherapy-induced nausea and vomiting	Introduction	2 min	Jørn Herrstedt	Denmark
	Emetic risk classification of antineoplastic agents	15 + 5 min	Paul Hesketh	USA
	Use of antiemetics targeting a single receptor	15 + 5 min	Karin Jordan	Germany
	Use of antiemetics targeting multiple receptors	15 + 5 min	David Warr	Canada
	Use of antiemetics in chemoradiation	12 + 3 min	Christina Ruhlmann	Denmark
Abstract 11-1-O	IMPACT AND MANAGEMENT OF CHEMOTHERAPY/ RADIOTHERAPY-INDUCED NAUSEA AND VOMITING AND THE PERCEPTUAL GAP BETWEEN ONCOLOGISTS/ONCOLOGY NURSES AND PATIENTS: A CROSS-SECTIONAL MULTINATIONAL SURVEY	7 + 3 min	Bahrat Amlani	United Kingdom
	Conclusion	3 min	Richard Gralla	USA

PARALLEL SESSION NUMBER 23

CHAIRMEN: Sharon Elad (USA) Ourania Nicolatou-Galitis (Greece)

ROOM CAPACITY: Medium

TIME: Saturday 14:45-16:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Mucositis	Introduction	2 min	Ourania Nicolatou-Galitis Greece
	Update on low level laser therapy for oral mucositis	18 + 4 min	Sharon Elad USA
	Updates on clinical studies of palifermin for oral and gastrointestinal mucositis	18 + 4 min	Nicole M. A. Blijlevens The Netherlands
	Stomatitis secondary to targeted anti-cancer agents	18 + 4 min	Ourania Nicolatou-Galitis Greece
Abstract 10-1-O	CLONIDINE MUCOADHESIVE BUCCAL TABLET (CLONIDINE LAURIAD) PREVENTS SEVERE RADIOMUCOSITIS IN HEAD AND NECK CANCER PATIENTS: A PHASE II RANDOMIZED TRIAL	7 + 3 min	Rene-Jean Bensadoun France
Abstract 10-2-O	EFFECTIVENESS OF LOW-LEVEL LASER THERAPY IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN CHILDREN	7 + 3 min	Alessandra Majorana Italy
	Conclusion	2 min	Sharon Elad USA

PARALLEL SESSION NUMBER 24

CHAIRMEN: Andrea Cheville (USA) and Ann-Dorthe Olsen Zwisler (Denmark)

ROOM CAPACITY: Large

TIME: Saturday 14:45-16:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Rehabilitation	Introduction	2 min	Andrea Cheville	USA
	Rehabilitation of older adults with cancer	15 + 5 min	Christoffer Steer	Australia
	Lessons to be learned from rehabilitation of non-cancer patients	15 + 5 min	Ann-Dorthe Olsen Zwisler	Denmark
	Optimization of Cancer Rehabilitation	20 + 5 min	Andrea Cheville	USA
Abstract 23-1-O	PATIENT ACTIVATION THROUGH COUNSELING AND EXERCISE – ACUTE LEUKEMIA (PACE-AL) TRIAL – A RANDOMIZED CONTROLLED TRIAL	8 + 3 min	Mary Jarden	Denmark
Abstract 23-2-O	THE MEDIATING ROLE OF PERCEIVED DISABILITY IN THE LONG-TERM IMPACT OF ARM MORBIDITY ON BREAST CANCER SURVIVORS' EMOTIONAL WELL-BEING	8 + 3 min	Thomas Hack	Canada
	Conclusion	1 min	Ann-Dorthe Olsen Zwisler	Denmark

PARALLEL SESSION NUMBER 25

CHAIRMEN: Declan Walsh (Ireland) and Eduardo Bruera (USA)

ROOM CAPACITY: Medium

TIME: Saturday 14:45-16:15

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Nutrition and cancer cachexia	Introduction	1 min	Declan Walsh	Ireland
14-1-O	SWALLOW ASSESSMENT IN HEAD AND NECK CANCER PATIENTS TREATED WITH MULTI-MODALITY THERAPY: COMPARISON OVER TIME OF SELF-REPORT, PHYSICAL EXAM FINDINGS AND OBJECTIVE MEASURES (R01 CA149113-01A1)	8 + 3 min	M Maddalo	Italy
14-2-O	DIETARY AND EXERCISE INTERVENTIONS TO IMPROVE QUALITY OF LIFE, METABOLIC RISK FACTORS AND ANDROGEN DEFICIENCY SYMPTOMS IN MEN WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY	8 + 3 min	L Teleni	Australia
14-3-O	CANCER MALNUTRITION AND CLINICAL OUTCOMES: RESULTS FROM TWO POINT PREVALENCE STUDIES IN AUSTRALIA	8 + 3 min	K Marshall	Australia
14-4-O	EXPLORING POTENTIAL BENEFIT OF EARLIER NUTRITIONAL INTERVENTIONS IN ADULTS WITH UPPER GASTROINTESTINAL CANCER: A RANDOMISED TRIAL	8 + 3 min	MA Silvers	Australia
02-1-O	RESULTS FROM ROMANA 1 AND 2: TWO PHASE III TRIALS OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH CACHEXIA	8 + 3 min	A Abernethy	USA
02-2-O	RESULTS FROM ROMANA 3: A SAFETY EXTENSION STUDY OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH CACHEXIA	8 + 3 min	D Currow	Australia
02-3-O	IMPACT OF CANCER CACHEXIA ON THE PHARMACOLOGY AND TOXICITY OF CHEMOTHERAPY (5-FU, PACLITAXEL) AND THE ORAL TYROSINE KINASE INHIBITOR ERLOTINIB: A RETROSPECTIVE PILOT STUDY (CAT)	8 + 3 min	F Strasser	Switzerland
02-4-O	VALIDATING ASSESSMENT OF SKELETAL MUSCLE MASS (SMM) AT L1 ON CHEST CT SCAN IN EVALUATING CANCER CACHEXIA (CC) AND SARCOPENIA IN PATIENTS WITH LUNG CANCER	8 + 3 min	A Recio-Boiles	USA
	Conclusion	1 min	Eduardo Bruera	USA

3 PLENARY SESSIONS

PLENARY SESSION NUMBER 1

CHAIRMEN: David Warr (Canada) and Jørn Herrstedt (Denmark)

ROOM CAPACITY: Large

TIME: Thursday 12:45-13:45

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Supportive Care is a Continuum	Introduction to session and Einhorn	2 min	David Warr	Canada
	Late Toxicities Induced by Anti-Neoplastic Agents; a Half Century Evaluation of Advantages and Challenges	28 min	Lawrence H Einhorn	USA
	Introduction Silver	1 min	Jørn Herrstedt	Denmark
	The Role of Prehabilitation and Rehabilitation in High-Quality Cancer Care	28 min	Julie Silver	USA
	Closure	1 min	Jørn Herrstedt	Denmark

PLENARY SESSION NUMBER 2

CHAIRMEN: David Warr (Canada) and Marianne Ewertz (Denmark)

ROOM CAPACITY: Large

TIME: Friday 11:00-12:00

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Pharmaceutical Supportive Care	Introduction to session and Chan	3 min	David Warr	Canada
Steven Grunberg Award Session	Pharmacogenomics in Supportive Care	18 min	Alexandre Chan	Singapore
	Introduction Lassen	1 min	Marianne Ewertz	Denmark
	Unmasking Side Effects from “First-in-Man” Antineoplastic Medicine	18 min	Ulrik Lassen	Denmark
	Introduction Keefe	1 min	David Warr	Canada
	New Developments in Personalised Supportive Care Medicine	18 min	Dorothy Keefe	Australia
	Closure	1 min	Marianne Ewertz	Denmark

PLENARY SESSION NUMBER 3

CHAIRMEN: Lawrence H Einhorn (USA) and Declan Walsh (IRL)

ROOM CAPACITY: Large

TIME: Saturday 09:00-10:00

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
The Oncologic Tsunami	Introduction to session and Gosney	2 min	Declan Walsh	Ireland
	Older Cancer Patients Survive – are we prepared?	28 min	Margot A Gosney	United Kingdom
	Introduction Olver	2 min	Lawrence H Einhorn	USA
	Reality of Supportive Care in the Developing World	28 min	Ian Olver	Australia
	Closure	1 min	Declan Walsh	Ireland

3 PRO ET CON SESSIONS

PRO ET CON SESSION NUMBER 1

CHAIRMEN: Alex Chan (Singapore)

ROOM CAPACITY: Medium

TIME: Thursday 16:15-17:15

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Antithrombotic agents for every patient with incurable cancer?	Introduction and voting	5 min	Alex Chan	Singapore
	PRO	20 min	Mario Dicato	Luxemburg
	CON	20 min	Florian Strasser	Switzerland
	Discussion and new voting	15 min	Alex Chan	Singapore

PRO ET CON SESSION NUMBER 2

CHAIRMAN: Sam Ahmedzai (United Kingdom)

ROOM CAPACITY: Large

TIME: Thursday 16:15-17:15

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Euthanasia, assisted dying	Introduction and voting	5 min	Sam Ahmedzai	United Kingdom
	PRO	20 min	Dominique Lossignol	Belgium
	CON	20 min	Gilles Freyer	France
	Discussion and new voting	15 min	Sam Ahmedzai	United Kingdom

PRO ET CON SESSION NUMBER 3

CHAIRMAN: Declan Walsh (Ireland)

ROOM CAPACITY: Large

TIME: Friday 17:45-18:45

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Parenteral nutrition in advanced cancer	Introduction and voting	5 min	Declan Walsh	Ireland
	PRO	20 min	Florian Strasser	Switzerland
	CON	20 min	Eduardo Bruera	USA
	Discussion and new voting	15 min	Declan Walsh	Ireland

7 CHALLENGE YOUR EXPERT SESSIONS

CHALLENGE YOUR EXPERT SESSION NUMBER 1

CHAIRMAN: Fausto Roila (Italy)

EXPERT: Mellar Davis (USA)

ROOM CAPACITY: Medium

TIME: Thursday 16:15-17:00

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Management of nausea and vomiting in advanced cancer	Introduction	3 min	Fausto Roila	Italy
	State of the art lecture	25 min	Mellar Davis	USA
	Discussion	15 min	All	
	Conclusion	2 min	Fausto Roila	Italy

CHALLENGE YOUR EXPERT SESSION NUMBER 2

CHAIRMAN: Eduardo Bruera (USA)

EXPERT: Declan Walsh (Ireland)

ROOM CAPACITY: Medium

TIME: Thursday 16:15-17:00

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Use of cannabinoids in cancer therapy and supportive care	Introduction	3 min	Eduardo Bruera	USA
	State of the art lecture	25 min	Declan Walsh	Ireland
	Discussion	15 min	All	
	Conclusion	2 min	Eduardo Bruera	USA

CHALLENGE YOUR EXPERT SESSION NUMBER 3

CHAIRMAN: Svend Saalbach Ottesen (Denmark)

EXPERT: Eduardo Bruera (USA)

ROOM CAPACITY: Medium

TIME: Saturday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER
Management of patients with delirium	Introduction	3 min	Svend Saalbach Ottesen Denmark
	State of the art lecture	25 min	Eduardo Bruera USA
	Discussion	15 min	All
	Conclusion	2 min	Svend Saalbach Ottesen Denmark

CHALLENGE YOUR EXPERT SESSION NUMBER 4

CHAIRMAN: Aminah Jatoi (USA)

EXPERT: Florian Strasser (Switzerland)

ROOM CAPACITY: Medium

TIME: Saturday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Nutrition and Cancer Cachexia	Introduction	3 min	Aminah Jatoi	USA
	State of the art lecture	25 min	Florian Strasser	Switzerland
	Discussion	15 min	All	
	Conclusion	2 min	Aminah Jatoi	USA

CHALLENGE YOUR EXPERT SESSION NUMBER 5

CHAIRMAN: Mellar Davis (USA)

EXPERT: Mario Dicato (Luxembourg)

ROOM CAPACITY: Medium

TIME: Saturday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Cancer and Thrombosis	Introduction	3 min	Mellar Davis	USA
	State of the art lecture	25 min	Mario Dicato	Luxembourg
	Discussion	15 min	All	
	Conclusion	2 min	Mellar Davis	USA

CHALLENGE YOUR EXPERT SESSION NUMBER 6

CHAIRMAN: Bernardo Rapoport (South Africa)

EXPERT: Jean Klastersky (Belgium)

ROOM CAPACITY: Medium

TIME: Saturday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Fever of Unknown Origin	Introduction	3 min	Bernardo Rapoport	South Africa
	State of the art lecture	25 min	Jean Klastersky	Belgium
	Discussion	15 min	All	
	Conclusion	2 min	Bernardo Rapoport	South Africa

CHALLENGE YOUR EXPERTS SESSION NUMBER 7

CHAIRMAN: Fred Ashbury (Canada)

EXPERTS: Fred Ashbury (Canada), Paul Hesketh (USA) and Ian Olver (Australia)

ROOM CAPACITY: Medium

TIME: Saturday 13:00-14:30

DURATION OF SESSION: 90 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
How to prepare and submit a paper for Supportive Care in Cancer	Introduction	5 min	Fred Ashbury	Canada
	The editors view	10 min	Fred Ashbury	Canada
	The authors view	20 min	Paul Hesketh	USA
	The reviewers view	20 min	Ian Olver	Australia
	Discussion	30 min	All	
	Conclusion	5 min	Fred Ashbury	Canada

6 PROFFERED PAPERS AND EXPERTS OPINIONS SESSIONS

PROFFERED PAPERS AND EXPERTS OPINIONS 1

CHAIRMEN AND EXPERTS: Dorothy Keefe (Australia) and Mario Lacouture (USA)

ROOM CAPACITY: Medium

TIME: Thursday 16.15-17:15

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Toxicity of targeted agents	Introduction to session and to toxicity of targeted agents	2 min	Dorothy Keefe	Australia
Abstract 25-1-O	META-ANALYSIS: HYPERTENSION RISK IN SELECTED TARGETED AGENTS	8 min	Carmelita Escalante	USA
Abstract 26-7-O	ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D)	8 min	Anders Mellemgard	Denmark
	Expert opinion abstracts 25-1-O and 26-5-O	12 min	Dorothy Keefe	Australia
Skin toxicity	Introduction skin toxicity	1 min	Mario Lacouture	USA
Abstract 20-1-O	LOW LEVEL LASER THERAPY FOR THE MANAGEMENT OF RADIATION DERMATITIS: FINAL RESULTS OF THE DERMIS TRIAL, A PILOT STUDY IN BREAST CANCER PATIENTS	8 min	Jeroen Mebis	Belgium
Abstract 20-2-O	PALMAR PLANTAR ERYTHRODYSESTHESIA PREVENTION WITH ATORVASTATIN AND POLYPRENOL	8 min	Sergejs Kuznecovs	Latvia
	Expert opinion abstracts 20-1-O and 20-2-O	12 min	Mario Lacouture	USA
	Closure	1 min	Mario Lacouture	USA

PROFFERED PAPERS AND EXPERTS OPINIONS 2

CHAIRMEN AND EXPERTS: Fausto Roila (Italy) and Charles Loprinzi (USA)

ROOM CAPACITY: Medium

TIME: Friday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Bone complications and chemotherapy-induced nausea and vomiting	Introduction	1 min	Fausto Roila	Italy
Abstract 27-3-O LBA	PREVALENCE OF LOW BONE MASS AND OSTEOPOROSIS IN WOMEN DIAGNOSED WITH GYNECOLOGIC CANCER	8 min	Beatrice Edwards	USA
Abstract 27-2-O LBA	A RANDOMIZED, PHASE 3, DOUBLE-BLIND STUDY OF INTRAVENOUS FOSAPREPITANT AS A SINGLE DOSE FOR PREVENTING HEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CHEMOTHERAPY	8 min	Bernardo Rapoport	South Africa
	Expert opinion abstracts 27-3-O and 27-2-O	12 min	Fausto Roila	Italy
Neurological complications	Introduction	1 min	Charles Loprinzi	USA
Abstract 27-1-O LBA	PREVENTION OF NEUROPATHY USING CALMANGAFODIPIR (PLEDOX®): RESULTS FROM A PHASE I STUDY AND A PLACEBO-CONTROLLED RANDOMIZED STUDY (PLIANT) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)	8 min	Bengt Glimelius	Sweden
	Expert opinion abstract 27-1-O	6 min	Charles Loprinzi	USA
	Closure	1 min	Charles Loprinzi	USA

PROFFERED PAPERS AND EXPERTS OPINIONS 3

CHAIRMEN AND EXPERTS: Florian Strasser (Switzerland) and Alexander Chan (Singapore)

ROOM CAPACITY: Small

TIME: Friday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Palliative Care	Introduction palliative care	1 min	Florian Strasser	Switzerland
Abstract 17-1-O	A DIAGNOSTIC MODEL FOR IMPENDING DEATH IN PATIENTS WITH ADVANCED CANCER	8 min	David Hui	USA
Abstract 05-1-O	PROGNOSTIC EVALUATION IN PALLIATIVE CARE: FINAL RESULTS FROM A PROSPECTIVE COHORT STUDY	8 min	Paola Ermacora	Italy
	Expert opinion abstracts 17-1-O and 05-1-O	12 min	Florian Strasser	Switzerland
Abstract 17-2-O	CHEMICAL COMPATIBILITY/STABILITY OF COMMONLY USED DRUG COMBINATIONS ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INFUSIONS FOR END OF LIFE CARE	8 min	Andrew Dickman	United Kingdom
	Expert opinion abstract 17-2-O	7 min	Alexander Chan	Singapore
	Closure	1 min	Alexander Chan	Singapore

PROFFERED PAPERS AND EXPERTS OPINIONS 4

CHAIRMEN AND EXPERTS: Rajesh Lalla (USA) and Alexis Molassiotis (Hong Kong)

ROOM CAPACITY: Small

TIME: Friday 16:30-17:30

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Evidence-based guidelines	Introduction to session and to development of guidelines	2 min	Rajesh Lalla	USA
Abstract 19-1-O	DEVELOPING AN EVIDENCE-BASED GUIDELINE FOR MANAGEMENT OF DYSPNEA IN CANCER PATIENTS: DESCRIPTION OF MASCC RESPIRATORY STUDY GROUP TASK	8 min	Sam Ahmedzai	United Kingdom
Abstract 25-2-O	PROACTIVE APPROACH: DEVELOPING AND IMPLEMENTING GUIDELINES FOR TREATING PATIENTS WITH ORALLY-ADMINISTERED ANTI-CANCER DRUGS (OAACD) IN THE HOME-CARE SETTING: EXPERIENCE OF A COMPREHENSIVE CANCER CENTER	8 min	Tal Granot	Israel
	Expert opinion abstracts 19-1-O and 25-2-O	12 min	Rajesh Lalla	USA
Education	Introduction education	1 min	Alex Molassiotis	Hong Kong
Abstract 04-3-O	ONCOLOGY NURSING SOCIETY (ONS) PUTTING EVIDENCE INTO PRACTICE (PEP): SYNTHESIS OF EVIDENCE BASED INTERVENTIONS FOR ADHERENCE TO ORAL AGENTS FOR CANCER	8 min	Cynthia Rittenberg	USA
Abstract 04-4-O	STRENGTHS, WEAKNESSES AND AREAS FOR IMPROVEMENTS: A COMPARATIVE SURVEY OF UNDERGRADUATE PALLIATIVE CARE (PC) EDUCATION ACROSS ALL UK MEDICAL SCHOOLS (MS)	8 min	Steven Walker	United Kingdom
	Expert opinion abstracts 04-2-O and 04-3-O	12 min	Alex Molassiotis	Hong Kong
	Closure	1 min	Alex Molassiotis	USA

PROFFERED PAPERS AND EXPERTS OPINIONS 5

CHAIRMEN AND EXPERTS: Ian Olver (Australia) and Mellar Davis (USA)

ROOM CAPACITY: Medium

DURATION OF SESSION: 60 min

TIME: Friday 16:30-17:30

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Palliative care	Introduction to session and to palliative care	2 min	Ian Olver	Australia
Abstract 17-3-O	EXPLORING THE COMPLEXITIES OF CAREGIVER QUALITY OF LIFE: QUALITATIVE RESULTS FROM A TRIAL OF EARLY PALLIATIVE CARE	8 min	Julie McDonald Young Investigator Winner	Canada
Abstract 17-4-O	DIFFERENCES IN ATTITUDES AND BELIEFS TOWARD CANCER TREATMENTS AT THE END-OF-LIFE BETWEEN HEMATOLOGIC AND SOLID TUMOR ONCOLOGY SPECIALISTS	8 min	David Hui	USA
	Expert opinion abstracts 17-3-O and 17-4-O	12 min	Ian Olver	Australia
Abstract 17-5-O	THE FREQUENCY, CHARACTERISTICS AND OUTCOMES AMONG CANCER PATIENTS WITH DELIRIUM ADMITTED TO AN ACUTE PALLIATIVE CARE UNIT (APCU)	8 min	Maxine de la Cruz	USA
Abstract 17-6-O	SLEEP DISTURBANCE CONTRIBUTES TO CRF IN CANCER PATIENTS WITH ACTIVE DISEASE	8 min	Diwakar Balachandran	USA
	Expert opinion abstracts 04-2-O and 04-3-O	12 min	Mellar Davis	USA
	Closure	2 min	Mellar Davis	USA

PROFFERED PAPERS AND EXPERTS OPINIONS 6

CHAIRMEN AND EXPERTS: Aminah Jatoi (USA) and Sam Ahmedzai (United Kingdom)

ROOM CAPACITY: Medium

TIME: Friday 16:30-17:30

DURATION OF SESSION: 60 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Pediatrics	Introduction to session and to pediatrics	2 min	Aminah Jatoi	USA
Abstract 16-1-O	DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR SUPPORTIVE CARE IN CHILDHOOD CANCER IN THE NETHERLANDS – CURRENT VARIATIONS IN SUPPORTIVE CARE PRACTICE	8 min	Erik Loeffen	The Netherlands
Abstract 16-2-O	TOXICITY IS ASSOCIATED WITH AGE AND BODY MASS INDEX IN NOPHO-AML 2004	8 min	Ditte Juel A Løhmann	Denmark
	Expert opinion abstracts 16-1-O and 16-2-O	12 min	Aminah Jatoi	USA
Patient Care	Introduction to care coordination	1 min	Sam Ahmedzai	United Kingdom
Abstract 26-1-O	CARE COORDINATION EXPERIENCE OF PATIENTS WITH COLORECTAL CANCER: A POPULATION BASED STUDY	8 min	Ivana Durcinoska	Australia
Abstract 26-6-O	PATIENT SATISFACTION WITH CANCER-RELATED CARE: LANGUAGE-BASED DIFFERENTIAL ITEM FUNCTIONING.	8 min	Jean-Pierre Pascal	USA
	Expert opinion abstracts	12 min	Sam Ahmedzai	United Kingdom
	Closure	1 min	Sam Ahmedzai	United Kingdom

1 POSTER DISCUSSION SESSION

POSTER DISCUSSION 1

CHAIRMEN AND EXPERTS: Jean Klastersky (Belgium) and Mario Dicato (Luxembourg)

ROOM CAPACITY: Medium

TIME: Friday 08:00-08:45

DURATION OF SESSION: 45 min

NAME OF SESSION	PRESENTATION TITLE	Minutes	SPEAKER	
Febrile neutropenia	Introduction febrile neutropenia	1 min	Jean Klastersky	Belgium
Abstract 13-2-O	Practical Application of a Febrile Neutropenia Pre-Printed Order /Algorithm Incorporating the MASCC Index within a Large Regional Emergency Department	3 min	Lee Ann Martin	Canada
Abstract 13-3-O	ASSESSMENT OF A NOMOGRAM FOR PREDICTING SERIOUS COMPLICATIONS IN PATIENTS FROM THE UNIVERSITY OF SALAMANCA HOSPITAL FEBRILE NEUTROPENIA REGISTRY	3 min	Ignacio Matos	Spain
Abstract 13-4-O	NORTHERN IRELAND'S EXPERIENCE OF IMPROVING INITIAL NEUTROPENIC SEPSIS MANAGEMENT THROUGH A MULTIDISCIPLINARY INTEGRATED CARE PATHWAY	3 min	Caroline Forde	United Kingdom
	Discussion abstracts 13-2-O, 13-3-O and 13-4-O	12 min	Jean Klastersky	Belgium
Anemia and thrombosis	Introduction anemia and thrombosis	1 min	Mario Dicato	Luxembourg
Abstract 08-1-O	TRAJECTORY OF HEMOGLOBIN LEVEL DURING TREATMENT OF SELECTED MYELOSUPPRESSIVE CHEMOTHERAPY REGIMENS FOR BREAST CANCER	3 min	Chun Chao	USA
Abstract 26-4-O	LEANING UPON INTERNATIONAL DIRECTIVES FOR OPTIMIZATION: ANEMIA	3 min	V Launay-Vacher	France
Abstract 21-1-O	VENOUS THROMBOLISM IN CANCER- A PROSPECTIVE STUDY	3 min	Aruna Alahari Dhir	India
	Discussions posters 08-1-O, 26-4-O and 21-1-O	12 min	Mario Dicato	Luxembourg
	Closure	1 min	Mario Dicato	Luxembourg

**IN ADDITION 5 SATELLITE SYMPOSIA AND ONE SPONSORED MEET THE
EXPERT SESSION (NOT PART OF THE SCIENTIFIC PROGRAMME)**